 Therefore researchers started to investigate modulations of the core structure to develop better agonists than melatonin; more potent, with better pharmacokinetics and longer half-life.TIK-301 (figure 1) is an agonist of the early classes.It is very similar to melatonin and has made it to clinical trials.